A pharmacoepidemiological claims data analysis revealed association of proton pump inhibitors (PPIs) with risk of dementia in the elderly. The prospective cohort study included a total of 73 679 participants 75 years of age or older and free of dementia at baseline between 2004 and 2011 from the largest German statutory health insurer. Data analysis was performed from August to November 2015. The association between PPI use and dementia was analyzed using time-dependent Cox regression. The model was adjusted for potential confounding factors, including age, sex, comorbidities, and polypharmacy. The patients receiving regular PPI medication (n = 2950; mean age, 83.8 years; 77.9% female) had a significantly increased risk of incident dementia compared with the patients not receiving PPI medication (n = 70 729; mean age, 83.0 years; 73.6% female). This finding is supported by recent pharmacoepidemiological analyses on primary data and is in line with mouse models in which the use of PPIs increased the levels of β-amyloid in the brains of mice, suggests that the avoidance of PPI medication may prevent the development of dementia. Source: http://archneur.jamanetwork.com/
一个药物流行病学索赔数据分析显示，质子泵抑制剂与老年痴呆症风险相关。该前瞻性群组研究共包括2004年至2011年间德国最大的法定医疗保险公司中73 679名75岁以上的参与者，开始时无痴呆症。在2015年八月至十一月间对服用质子泵抑制剂和痴呆之间的关联进行了时间依赖性Cox回归分析。该模型校正了潜在的混杂因素，包括年龄，性别，合并症和多重用药。与未接受质子泵抑制剂治疗者（70 729人，平均年龄83.0岁; 73.6 ％为女性）相比，经常接受质子泵抑制剂治疗的患者（2950人，平均年龄83.8岁，77.9％为女性）发生痴呆症的风险显著增加。最近的药物流行病学主数据分析支持这一发现，且与大鼠模型中使用质子泵抑制剂增加大鼠脑中β淀粉样蛋白水平一致，提示避免服用质子泵抑制剂有可能预防痴呆的发生。来源：http://archneur.jamanetwork.com/